Title
Category
Credits
Event date
Cost
Part 4: Balancing Safety and Efficacy with Novel Schizophrenia Treatments
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
Part 1: A Review of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
Part 2: Chasing Cognitive and Negative Symptoms: Unmet Treatment Needs of Patients with Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
Part 3: Impact of Side Effects on Adherence to Schizophrenia Treatment
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia.
Tweetorial: Analyzing Two Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.